VERU INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
VERU INC. (VERU) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $231.93 thousand as of 2018-12-31, per its 10-Q filed 2019-02-13.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2019-02-13
- 2018-12-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $231.93K.
- 2018-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $68.81K.
- 2018-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $137.63K.
- 2017-12-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $206.45K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2018-12-31 | $231.93K 10-Q · filed 2019-02-13 |
| 2018-06-30 | $68.81K 10-Q · filed 2018-08-14 |
| 2018-03-31 | $137.63K 10-Q · filed 2018-05-11 |
| 2017-12-31 | $206.45K 10-Q · filed 2018-02-14 |
| 2017-06-30 | $40.09K 10-Q · filed 2017-08-09 |
| 2017-03-31 | $80.19K 10-Q · filed 2017-05-10 |
| 2016-12-31 | $120.28K 10-Q · filed 2017-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |